TTF-1、P40共表达且EGFR-TKI原发性耐药的低分化NSCLC患者1例并文献复习  

Poorly differentiated NSCLC with co-expressions of TTF-1 and P40 and primary resistance to EGFR-TKI:a case report and literature review

作　　者：文雪梅[1] 潘春霞[1] Wen Xuemei;Pan Chunxia(Second Department of Oncology,the Third People′s Hospital of Dalian,Dalian 116033,China)

机构地区：[1]大连市第三人民医院肿瘤内科二病房,大连116033

出　　处：《国际呼吸杂志》2024年第12期1452-1459,共8页International Journal of Respiration

摘　　要：TTF-1、P40共表达的低分化非小细胞肺癌是一种罕见的病理类型,其侵袭性强,恶性程度高,同时具有腺癌和鳞癌的标志物表达,生物学行为特殊,治疗反应不同。部分患者虽存在EGFR基因敏感突变,其一线表皮生长因子受体-酪氨酸激酶抑制剂治疗仍出现原发性耐药,但含铂双药方案化疗联合免疫治疗的疗效极佳。现报道相关病例1例,结合国内外文献对其特点进行分析,旨在了解这类非小细胞肺癌患者的治疗方法,分析疗效并判断预后。Poorly differentiated non-small cell lung cancer(NSCLC)with co-expressions of TTF-1 and P40 is a rare pathological type,characterized by strong invasiveness,high malignancy,and positive expressions of biomarkers for adenocarcinomas and squamous cell carcinomas.Its biological behavior is unique,and the treatment response varies.Although some patients have epidermal growth factor receptor(EGFR)gene mutations,they present primary resistance to the first-line EGFR-tyrosine kinase inhibitor(EGFR-TKI)treatment,but respond well to the platinum-containing dual-drug chemotherapy combined with immunotherapy.This paper reports a case of poorly differentiated NSCLC with co-expressions of TTF-1 and P40 and primary resistance to EGFR-TKI.Through analyzing this case and literature review,this paper aims to provide details in the treatment,evaluation of the efficacy and prediction of the prognosis in this rare disease.

关 键 词：癌 非小细胞肺 TTF-1 P40 基因 erbB-1 原发性耐药 免疫检查点抑制剂 

分 类 号：R73[医药卫生—肿瘤]